US drug tariffs threaten India's generic medicine sector, exposing global trade inequities and supply‑chain vulnerabilities
Original framing: “Will Trump’s proposed drug tariffs end India’s reign as ‘pharmacy of the world’?” — South China Morning Post
Scientific evidence demonstrates that Indian generic manufacturers meet WHO pre‑qualification standards for quality, safety, and efficacy, underpinning their role in global health security. Studies also indicate that abrupt tariff increases would raise drug prices by 10‑30 % in low‑income markets, potentially leading to treatment interruptions. Robust data on supply‑chain resilience are essential for policy decisions that balance domestic industry protection with global health needs.
The proposed US tariffs are a flashpoint where protectionist politics, entrenched global health inequities, and supply‑chain fragilities intersect.
Historical precedents show that such measures rarely achieve their stated goals of domestic health security, instead amplifying price barriers for the world’s most vulnerable patients. By foregrounding marginalized patient voices, integrating indigenous and scientific knowledge, and learning from cross‑cultural models of regional manufacturing, policymakers can redesign trade frameworks that safeguard both national interests and global health. Future‑oriented scenario planning, coupled with health‑impact assessments, offers a disciplined pathway to transform a potentially disruptive policy into an opportunity for a more resilient, equitable pharmaceutical ecosystem.